Physician profile
Gabriel Reed Archer
NPI 1245950153
$961.73
in general payments reported to CMS, 2019-2025
16 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.83 · 2023: $155 · 2024: $360 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $935 · Education: $8.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $935.35 |
| Education | $8.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $298.04 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $135.38 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $102.07 | 2024-2025 | Auvelity |
| Corcept Therapeutics | $79.82 | 2024 | Korlym |
| Otsuka America Pharmaceutical, INC. | $69.46 | 2023-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $52.10 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $42.53 | 2023 | Spravato |
| Glaxosmithkline, LLC. | $37.27 | 2024 | Trelegy Ellipta |
| Cequr Corporation | $20.86 | 2024 | Cequr Simplicity |
| Tris Pharma INC | $20.52 | 2024 | Dyanavel Xr |
| Philips North America LLC | $19.91 | 2024 | (Ck7) Extended Holter |
| Amphastar Pharmaceuticals, INC. | $18.69 | 2024 | |
| Novo Nordisk INC | $17.83 | 2022 | |
| Xeris Pharmaceuticals, INC. | $17.56 | 2025 | Gvoke Hypopen |
| Alkermes, INC. | $16.12 | 2023 | Aristada, Lybalvi |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13.57 | 2024 | Gardasil, Vaxelis, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Archer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.